

Leiping Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2684364/publications.pdf>

Version: 2024-02-01

40
papers

716
citations

567281

15
h-index

580821

25
g-index

40
all docs

40
docs citations

40
times ranked

1421
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. <i>Investigational New Drugs</i> , 2022, 40, 330-339.	2.6	10
2	Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. <i>Frontiers in Oncology</i> , 2022, 12, 775081.	2.8	8
3	Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. <i>Oncologist</i> , 2021, 26, e580-e587.	3.7	7
4	An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 1238-1248.	1.0	0
5	Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1035-1035.	1.6	1
6	Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15026-e15026.	1.6	0
7	Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1075-1075.	1.6	0
8	Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 684.	6.3	27
9	Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. <i>Annals of Palliative Medicine</i> , 2021, 10, 11255-11264.	1.2	13
10	Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. <i>BMC Cancer</i> , 2021, 21, 1174.	2.6	1
11	Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 8821-8831.	2.8	4
12	PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR. <i>Molecular Medicine Reports</i> , 2020, 21, 2209-2219.	2.4	7
13	Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 719-726.	2.5	3
14	miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382090582.	1.9	22
15	<p>Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 607-615.	2.0	3
16	Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. <i>Investigational New Drugs</i> , 2020, 38, 507-514.	2.6	12
17	Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. <i>Cancer Research and Treatment</i> , 2020, 52, 1059-1066.	3.0	26
18	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	8
20	Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, e452-e458.	2.4	5
21	Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 3563.	3.3	4
22	Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study. <i>Scientific Reports</i> , 2019, 9, 1710.	3.3	4
23	Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 389-399.	2.5	21
24	Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. <i>BMC Cancer</i> , 2018, 18, 1019.	2.6	19
25	Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 446.	2.6	74
26	An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 10714-10722.	1.8	20
27	A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. <i>Hematology</i> , 2017, 22, 258-264.	1.5	8
28	A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. <i>Scientific Reports</i> , 2017, 7, 6584.	3.3	30
29	Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment. <i>Tumor Biology</i> , 2017, 39, 101042831771103.	1.8	19
30	Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 79527-79536.	1.8	2
31	A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 84224-84236.	1.8	47
32	GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 105905-105914.	1.8	12
33	Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. <i>Oncology Reports</i> , 2016, 36, 2071-2078.	2.6	31
34	Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 U/L. <i>Tumor Biology</i> , 2016, 37, 14083-14088.	1.8	50
35	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	1.8	6
36	Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2-Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane. <i>PLoS ONE</i> , 2015, 10, e0118607.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS ONE, 2015, 10, e0133133.	2.5	7
38	Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. Oncotarget, 2015, 6, 43135-43143.	1.8	36
39	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine, 2014, 9, 1443.	6.7	19
40	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 2011, 11, 248.	2.6	135